1st Jul 2015 08:58
LONDON (Alliance News) - Lifeline Scientific Inc on Wednesday said a meta-analysis study has been published in The American Surgeon journal which supports an expanded use of machine perfusion.
The company said the study found machine perfusion of donated kidneys, which can be carried out by Lifeline's LifePort Kidney Transporter, was beneficial in delaying graft function on standard donors and not just in donation after cardiac death.
"This is compelling news for patients, payors, and transplant centres as reportedly almost half of the deceased donor kidneys that present in North America every year come from standard criteria donors. Whilst there is wide spread clinical support for the benefits of using LifePort on ECD and DCD kidneys, the use of LifePort on SCD kidneys has not been universally adopted," said David Kravitz, Lifeline's chief executive.
"These important findings show that using LifePort routinely for all donor kidneys, and not just marginal organs, could significantly benefit patient outcomes when compared to the common practice of simply storing donor kidneys in a box of ice," Kravitz added.
Shares in Lifeline were up 5.9% to 197.00 pence on Wednesday.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
LSIC.L